[go: up one dir, main page]

CL2022000038A1 - Conjugados peptídicos de citotoxinas como terapéuticos. - Google Patents

Conjugados peptídicos de citotoxinas como terapéuticos.

Info

Publication number
CL2022000038A1
CL2022000038A1 CL2022000038A CL2022000038A CL2022000038A1 CL 2022000038 A1 CL2022000038 A1 CL 2022000038A1 CL 2022000038 A CL2022000038 A CL 2022000038A CL 2022000038 A CL2022000038 A CL 2022000038A CL 2022000038 A1 CL2022000038 A1 CL 2022000038A1
Authority
CL
Chile
Prior art keywords
cytotoxins
therapeutics
peptide conjugates
conjugates
peptide
Prior art date
Application number
CL2022000038A
Other languages
English (en)
Inventor
Daniel Richard Marshall
Johanna Marie Csengery
Robert A Volkmann
Robert John Maguire
Original Assignee
Cybrexa 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 2 Inc filed Critical Cybrexa 2 Inc
Publication of CL2022000038A1 publication Critical patent/CL2022000038A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a conjugados peptídicos de citotoxinas tales como inhibidores de topoisomerasa I que son útiles para el tratamiento de enfermedades tal como cáncer.
CL2022000038A 2019-07-10 2022-01-06 Conjugados peptídicos de citotoxinas como terapéuticos. CL2022000038A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872643P 2019-07-10 2019-07-10
US202063040859P 2020-06-18 2020-06-18

Publications (1)

Publication Number Publication Date
CL2022000038A1 true CL2022000038A1 (es) 2022-08-19

Family

ID=71787212

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000038A CL2022000038A1 (es) 2019-07-10 2022-01-06 Conjugados peptídicos de citotoxinas como terapéuticos.

Country Status (19)

Country Link
US (2) US11634508B2 (es)
EP (1) EP3997093A1 (es)
JP (2) JP7673041B2 (es)
KR (1) KR20220052918A (es)
CN (1) CN114341162B (es)
AU (1) AU2020309570A1 (es)
BR (1) BR112022000337A2 (es)
CA (1) CA3146560A1 (es)
CL (1) CL2022000038A1 (es)
CO (1) CO2022001316A2 (es)
CR (1) CR20220058A (es)
EC (1) ECSP22010228A (es)
IL (1) IL289658A (es)
MX (1) MX2022000449A (es)
MY (1) MY208881A (es)
PE (1) PE20220563A1 (es)
PH (1) PH12022550039A1 (es)
TW (1) TW202116778A (es)
WO (1) WO2021007435A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
EP4223318A4 (en) 2020-09-30 2024-12-18 Duality Biologics (Suzhou) Co., Ltd. Antitumor compound, and preparation method therefor and use thereof
EP4274905A1 (en) 2021-01-08 2023-11-15 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
CA3218253A1 (en) 2021-04-29 2022-11-03 Cybrexa 2, Inc. Dosing regimens of peptide conjugates of topoisomerase i inhibitors
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
JP2024542212A (ja) * 2021-11-17 2024-11-13 サイブレクサ ４，インコーポレイテッド 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート
TWI864640B (zh) * 2022-03-18 2024-12-01 大陸商映恩生物製藥（蘇州）有限公司 Gpc3抗體藥物偶聯物及其用途
WO2023191209A1 (ko) * 2022-03-29 2023-10-05 주식회사 퓨전바이오텍 친수성 펩타이드를 포함하는 마이셀 및 이의 용도
WO2024212922A1 (zh) * 2023-04-11 2024-10-17 映恩生物制药（苏州）有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
WO2025054707A1 (en) * 2023-09-11 2025-03-20 Theratechnologies Inc. Peptide conjugates of camptothecin analogs and uses thereof
WO2025168066A1 (zh) * 2024-02-08 2025-08-14 映恩生物制药（苏州）有限公司 喜树碱类化合物及其偶联物、其制备方法和用途

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004771A1 (en) 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
US5637770A (en) 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
PT897924E (pt) 1996-04-26 2002-03-28 Daiichi Seiyaku Co Processo para a preparacao de tetra-hidroindolizinas
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
IN189180B (es) 1997-07-09 2003-01-04 Chong Kun Dang Corp
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
EP1155702A4 (en) 1998-10-30 2004-12-15 Daiichi Seiyaku Co DDS CONNECTIONS AND TEST METHODS
KR20010100977A (ko) 1998-11-03 2001-11-14 스타르크, 카르크 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
WO2001041534A2 (en) 1999-12-13 2001-06-14 Eli Lilly And Company Pseudomycin phosphate prodrugs
BR0109266A (pt) 2000-03-15 2003-04-29 Bristol Myers Squibb Pharma Co Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
MXPA03000387A (es) 2000-07-13 2003-09-22 Daiichi Seiyaku Co Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina-1.
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP4477881B2 (ja) 2002-03-01 2010-06-09 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 治療剤または細胞毒性剤と生物活性ペプチドとの抱合体
NZ535365A (en) 2002-03-20 2006-07-28 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0408996A (pt) 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1651162B1 (en) 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
BRPI0412899B1 (pt) 2003-07-25 2021-10-05 Cancer Research Technology Limited Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático
EP1684736B1 (en) 2003-12-01 2011-08-24 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
WO2005112919A2 (en) * 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
EP1789391B1 (en) * 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
KR20090130156A (ko) 2004-09-22 2009-12-17 화이자 인코포레이티드 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물
ES2382950T3 (es) 2004-09-22 2012-06-14 Pfizer, Inc. Formas polimorfas de la sal de fosfato de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepin[5,4,3-cd]indol-6-ona
KR100876520B1 (ko) 2004-09-22 2008-12-31 화이자 인코포레이티드 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법
DK1819359T3 (en) 2004-12-09 2015-04-20 Janssen Biotech Inc ANTI-integrin immunoconjugates, processes for their preparation and their use
EP1846014B1 (en) 2005-01-18 2012-10-24 The Board of Governors for Higher Education State of Rhode Island and Providence Plantations Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally sensitive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
CA2597407C (en) 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2006113623A2 (en) 2005-04-15 2006-10-26 Immunogen, Inc. Elimination of heterogeneous or mixed cell population in tumors
NZ595430A (en) 2005-08-24 2013-05-31 Immunogen Inc Process for preparing maytansinoid antibody conjugates
EP1957477B1 (en) 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
PL1945647T3 (pl) 2005-11-08 2012-04-30 Immunogen Inc Procesy wytwarzania maytansinolu
DK2338487T3 (da) 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
CN101479295A (zh) 2006-05-04 2009-07-08 健泰科生物技术公司 涉及zpa多肽的方法和组合物
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
DK2805945T3 (da) 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
PT2187965T (pt) * 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
AU2009253892B2 (en) 2008-06-05 2015-07-30 Janssen Pharmaceutica Nv Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
WO2010141566A1 (en) 2009-06-03 2010-12-09 Immunogen, Inc. Conjugation methods
WO2011066418A1 (en) 2009-11-25 2011-06-03 Academia Sinica The tumor-selective anti-cancer prodrug bqc-g
SG10201406805RA (en) 2010-02-12 2014-11-27 Pfizer Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
CN103025165B (zh) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
EP4321168A3 (en) 2010-07-13 2024-04-24 Yale University, Inc. Environmentally sensitive compositions
EP2603201B1 (en) 2010-08-13 2020-03-11 Rhode Island Board of Governors for Higher Education Liposome compositions and methods of use thereof
CN103269712B (zh) 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
WO2012135522A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
IL302494B2 (en) 2012-10-11 2024-11-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates and methods for their preparation
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
US9180203B2 (en) 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
WO2014093343A2 (en) 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
WO2014107024A1 (ko) 2013-01-03 2014-07-10 셀트리온 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
MX385651B (es) 2013-12-19 2025-03-18 Seagen Inc Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.
WO2015108986A1 (en) 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
PT3789042T (pt) * 2014-04-10 2025-01-14 Daiichi Sankyo Europe Gmbh Método para produzir conjugado anticorpo-fármaco anti-her3
JP6612738B2 (ja) 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
KR102407261B1 (ko) 2015-02-27 2022-07-06 서울대학교산학협력단 나노 항암제형 및 그 제조 방법
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3368546A4 (en) 2015-10-28 2019-06-26 Tarveda Therapeutics, Inc. AGAINST SSTR CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
HUE049775T2 (hu) 2015-11-24 2020-10-28 Theravance Biopharma R&D Ip Llc Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
US20200078468A1 (en) * 2016-04-13 2020-03-12 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
US20190133980A1 (en) 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
CA3032401A1 (en) 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
CN109563128B (zh) 2016-08-16 2023-02-28 国立研究开发法人产业技术总合研究所 恶性肿瘤靶向肽
CA3037241A1 (en) 2016-09-22 2018-03-29 Rhode Island Council On Postsecondary Education Fluorescent compound comprising a fluorophore conjugated to a ph-triggered polypeptide
CN110088086B (zh) 2016-11-25 2022-12-16 迈威(上海)生物科技股份有限公司 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
EP3554638B1 (en) 2016-12-19 2022-02-02 Morehouse School of Medicine Compositions and methods for treating diseases by inhibiting exosome release
EP3634498A4 (en) 2017-06-09 2021-08-25 Rhode Island Council on Postsecondary Education BOUND COMPOUNDS AND OTHER PH ACTIVATED COMPOUNDS
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
JP2021510701A (ja) 2018-01-12 2021-04-30 プロリンクス エルエルシー 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
EP3917528A4 (en) 2019-01-28 2022-12-28 University of Rhode Island Board of Trustees Phlip® targeted delivery of potent cytotoxic compounds
EP3946464B1 (en) 2019-03-29 2022-08-31 MedImmune Limited Compounds and conjugates thereof
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
EP4274905A1 (en) 2021-01-08 2023-11-15 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
CA3218253A1 (en) 2021-04-29 2022-11-03 Cybrexa 2, Inc. Dosing regimens of peptide conjugates of topoisomerase i inhibitors
JP2024542212A (ja) 2021-11-17 2024-11-13 サイブレクサ ４，インコーポレイテッド 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート

Also Published As

Publication number Publication date
JP7673041B2 (ja) 2025-05-08
BR112022000337A2 (pt) 2022-04-12
CA3146560A1 (en) 2021-01-14
CN114341162B (zh) 2025-10-17
MY208881A (en) 2025-06-05
CN114341162A (zh) 2022-04-12
US20210009719A1 (en) 2021-01-14
TW202116778A (zh) 2021-05-01
AU2020309570A1 (en) 2022-02-03
US11634508B2 (en) 2023-04-25
PE20220563A1 (es) 2022-04-13
US20240010755A1 (en) 2024-01-11
WO2021007435A1 (en) 2021-01-14
CO2022001316A2 (es) 2022-05-10
PH12022550039A1 (en) 2023-06-26
KR20220052918A (ko) 2022-04-28
ECSP22010228A (es) 2022-05-31
MX2022000449A (es) 2022-04-25
JP2025114615A (ja) 2025-08-05
IL289658A (en) 2022-03-01
JP2022541749A (ja) 2022-09-27
EP3997093A1 (en) 2022-05-18
US12410262B2 (en) 2025-09-09
CR20220058A (es) 2022-07-19

Similar Documents

Publication Publication Date Title
CO2022001316A2 (es) Conjugados peptídicos de citotoxinas como terapéuticos
CO2022004694A2 (es) Heterociclos bicíclicos como inhibidores de fgfr
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
ECSP20069404A (es) Piridazinonas como inhibidoras de parp7
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
MX2022014648A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
CO2021017845A2 (es) Proteínas multiespecíficas
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
CO2022001315A2 (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
CR20160396A (es) Ciclopropilamina como inhibidores de la lsd1
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
CL2024001486A1 (es) Conjugados peptidicos de inhibidores peptidicos de tubulina como terapeuticos.
ECSP20082988A (es) Agonistas de tlr7
ECSP15001225A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos